Moderna Drops Norovirus Vaccine Trial Cohort

The mRNA-1403 program remains in research-stage testing while regulators weigh its next steps.

Updated on Nov. 6, 2026 in Biotech

Bold flat-color editorial illustration of unlabeled glass vials in a cold-storage tray under a shaft of cool light, in navy and cream.
Moderna has dropped plans to enroll a new cohort in the phase 3 trial of its norovirus vaccine candidate mRNA-1403, pending talks with regulators. AI Illustration. Upload story photo >

Moderna has scrapped plans to enroll a new cohort in its phase 3 trial of mRNA-1403, its norovirus vaccine candidate, and will meet with regulators to decide next steps. The program remains in clinical testing and has not been approved or made available to patients.

Why it matters

The decision narrows the path for an mRNA vaccine against norovirus, a common cause of acute gastroenteritis, after a series of setbacks including a missed interim analysis and an FDA clinical hold. It also signals how a major mRNA developer is trimming costly late-stage programs as it reprioritizes its pipeline.

The company attributed the 27% R&D drop to lower clinical development costs and cost efficiencies rather than to a specific efficacy figure for the vaccine. The extraction does not include efficacy data for mRNA-1403, so the trial's measured results cannot be assessed from the available information.

The players

Moderna

A U.S. mRNA biotechnology company whose platform underpins its vaccine and therapeutic pipeline, including mRNA-1403 and intismeran autogene.

U.S. Food and Drug Administration (FDA)

The U.S. federal regulator that placed mRNA-1403 on clinical hold in February 2025 and oversees the program's regulatory status.

Merck & Co.

A global pharmaceutical company that is partnering with Moderna on intismeran autogene, an mRNA-based cancer therapy.

European Society for Medical Oncology (ESMO)

The European professional society for cancer medicine whose conference hosted new phase 3 melanoma data for intismeran autogene.

The details

mRNA-1403 is a trivalent vaccine built on messenger RNA, a genetic instruction molecule that cells read to produce a viral protein and so trigger an immune response. It is designed to prevent acute gastroenteritis, the inflammation of the stomach and intestines caused by norovirus infection. Moderna launched the phase 3 trial in September 2024 but disclosed in July that the candidate missed its interim analysis, a checkpoint at which investigators review accumulating data. The FDA then placed the program on hold in February 2025 over a reported case of Guillain-Barré syndrome, a rare nerve disorder, and the study later had to continue into a second Northern Hemisphere season after too few cases accrued in the Southern Hemisphere.

Timeline

  1. September 2024: Moderna launched the phase 3 trial of mRNA-1403.

  2. February 2025: The FDA placed the program on hold over a reported Guillain-Barré case.

  3. November 2025: The study was extended into a second Northern Hemisphere season.

  4. November 6, 2026: Moderna announced on its earnings call that the new cohort enrollment was scrapped.

The Tech Race

Moderna's norovirus program is one of several mRNA vaccine candidates pursued by developers seeking to extend the platform beyond COVID-19. The company is simultaneously advancing intismeran autogene with Merck & Co. in melanoma, where new phase 3 data were presented at ESMO, which shows where its late-stage resources are being directed.

No norovirus vaccine based on this candidate is available to the public, and the program now faces an undetermined regulatory path. Patients should not expect access to mRNA-1403 in the near term, as the timeline for any future filing has not been announced.

The takeaway

Watch for Moderna's post-meeting update on mRNA-1403, which will indicate whether the norovirus program is advanced in a modified form or wound down. The company's remaining late-stage work, including the Merck partnership on intismeran autogene, will show where mRNA resources are being concentrated.

What happens next

Moderna will meet with regulators to decide next steps for mRNA-1403 and will provide further updates following those discussions with health authorities.

Further reading

For more on how companies like this are steering drug development, explore our Biotech coverage.

Source note: This article includes information reported by FierceBiotech - free daily biotech briefing.